Scholarlink

Background <p>The role of neoadjuvant treatment and its modalities in the risk of complications after esophagectomy in national practice is unclear. The aim of this study was to compare postoperative complications after neoadjuvant treatment (nT) and upfront surgery (US), neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT), and to assess the effect of complications from neoadjuvant treatment in surgical risk.</p> Patients and Methods <p>All patients undergoing esophagectomy for esophageal cancer in Finland in 2005–2016 were included. Incidences of all postoperative complications defined by the Esophagectomy Complications Consensus Group as well as major complications, 90-day mortality, and hospital and ICU stay were reported stratified by treatment strategy (nT versus US, nCRT versus nCT, nT-complication versus no complication). Primary outcomes were compared using logistic regression in these patient groups.</p> Results <p>Out of 774 patients, 423 (55%) had nT and 351 (45%) had US. Of the 423 patients undergoing nT, 249 (59%) had nCT, 3 (1%) had radiotherapy only, and 171 (40%) had nCRT. After adjusting for relevant confounders, there were no increases in pneumonia, anastomotic leak, major complications, overall complications, or 90-day mortality with nT compared with US, nCRT compared with nCT, or in patients with nT complications compared with those without.</p> Conclusions <p>This nationwide, population-based study reports no difference in postoperative complications or mortality after nT compared with US or nCRT compared with nCT. Patients with neoadjuvant treatment complications were not at higher risk of postoperative complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoadjuvant Treatment and Postoperative Complications After Surgery for Esophageal Cancer: A Population-Based, Nationwide Study in Finland

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月6日

查看全文
  • Ville E. J. Sirviö,
  • Jari V. Räsänen,
  • Olli Helminen,
  • Mika Helmiö,
  • Heikki Huhta,
  • Raija Kallio,
  • Vesa Koivukangas,
  • Arto Kokkola,
  • Elina Lietzen,
  • Sanna Meriläinen,
  • Vesa-Matti Pohjanen,
  • Tuomo Rantanen,
  • Ari Ristimäki,
  • Juha Saarnio,
  • Eero Sihvo,
  • Tuula Tyrväinen,
  • Mikko Uimonen,
  • Antti Valtola,
  • Joonas H. Kauppila

摘要

Background

The role of neoadjuvant treatment and its modalities in the risk of complications after esophagectomy in national practice is unclear. The aim of this study was to compare postoperative complications after neoadjuvant treatment (nT) and upfront surgery (US), neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT), and to assess the effect of complications from neoadjuvant treatment in surgical risk.

Patients and Methods

All patients undergoing esophagectomy for esophageal cancer in Finland in 2005–2016 were included. Incidences of all postoperative complications defined by the Esophagectomy Complications Consensus Group as well as major complications, 90-day mortality, and hospital and ICU stay were reported stratified by treatment strategy (nT versus US, nCRT versus nCT, nT-complication versus no complication). Primary outcomes were compared using logistic regression in these patient groups.

Results

Out of 774 patients, 423 (55%) had nT and 351 (45%) had US. Of the 423 patients undergoing nT, 249 (59%) had nCT, 3 (1%) had radiotherapy only, and 171 (40%) had nCRT. After adjusting for relevant confounders, there were no increases in pneumonia, anastomotic leak, major complications, overall complications, or 90-day mortality with nT compared with US, nCRT compared with nCT, or in patients with nT complications compared with those without.

Conclusions

This nationwide, population-based study reports no difference in postoperative complications or mortality after nT compared with US or nCRT compared with nCT. Patients with neoadjuvant treatment complications were not at higher risk of postoperative complications.